(S (NP-SBJ (DT The) (NN candidate) (NN oncoprotein) (NN Bcl-3)) (VP (VBZ is) (NP-PRD (NP (DT an) (NN antagonist)) (PP (IN of) (NP (ADJP (NN (NF-kappa p50)) (JJ B-mediated)) (NN inhibition))))) (. .))
(S (NP-SBJ-18 (DT The) (NN candidate) (NN oncogene) (NN bcl-3)) (VP (VBD was) (VP (VBN discovered) (NP (-NONE- *-18)) (PP (IN as) (NP (NP (DT a) (NN translocation)) (PP (IN into) (NP (DT the) (NN immunoglobulin) (NN alpha-locus))))) (PP (IN in) (NP (NP (DT some) (NNS cases)) (PP (IN of) (NP (NN B-cell) (JJ chronic) (JJ lymphocytic) (NNS leukaemias))))))) (. .))
(S (NP-SBJ (DT The) (NN protein) (NN Bcl-3)) (VP (VBZ contains) (NP (CD seven) (JJ so-called) (NN ankyrin) (NNS repeats))) (. .))
(S-COOD (S (NP-SBJ-19 (JJ Similar) (NN repeat) (NNS motifs)) (VP (VBP are) (VP (VBN found) (NP (-NONE- *-19)) (PP (IN in) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ diverse) (JJ regulatory) (NNS proteins)))))))) (CC but) (S (NP-SBJ (NP (DT the) (NNS motifs)) (PP (IN of) (NP (NN Bcl-3)))) (VP (VBP are) (ADJP-PRD (ADVP (RBS most) (RB closely)) (JJ related) (PP (TO to) (NP (NP (DT those)) (VP (VBN found) (NP (-NONE- *)) (PP (IN in) (NP (NP (NN I) (NN kappa) (NN B) (NNS proteins)) (SBAR (WHPP-21 (IN in) (WHNP (WDT which))) (S (NP-SBJ-22 (DT the) (NN ankyrin) (NN repeat) (NN domain)) (VP (VBZ is) (VP (VBN thought) (S (NP-SBJ-23 (-NONE- *-22)) (VP (TO to) (VP (VB be) (ADVP (RB directly)) (VP (VBN involved) (NP (-NONE- *-23)) (PP (IN in) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN activity))))) (PP (-NONE- *T*-21)))))))))))))))))) (. .))
(S-COOD (S (NP-SBJ-24 (DT No) (JJ biological) (NN function)) (VP (VBZ has) (ADVP (RB yet)) (VP (VBN been) (VP (VBN described) (NP (-NONE- *-24)) (PP (IN for) (NP (NN Bcl-3))))))) (, ,) (CC but) (S (NP-SBJ (PRP it)) (VP (VBD was) (VP (VBN noted) (ADVP-TMP (RB recently)) (SBAR (IN that) (S (NP-SBJ (NN Bcl-3)) (VP (VBZ interferes) (PP (IN with) (NP (NP (NN DNA-binding)) (PP (IN of) (NP (NP (DT the) (NN p50) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))) (ADVP (FW in) (FW vitro)))))))) (. .))
(S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-25 (NN Bcl-3)) (VP (MD can) (VP (VB aid) (NP (ADJP (NN kappa) (NN B) (JJ site-dependent)) (NN transcription)) (ADVP (FW in) (FW vivo)) (PP (IN by) (S (NP-SBJ (-NONE- *-25)) (VP (VBG counteracting) (NP (NP (DT the) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NN (NF-kappa p50)) (NN B) (NNS homodimers)))))))))))) (. .))
(S (NP-SBJ (NN Bcl-3)) (VP (MD may) (ADVP (RB therefore)) (VP (VB aid) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ select) (ADJP (NN NF-kappa) (JJ B-regulated)) (NNS genes)) (, ,) (PP (VBG including) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus)))))))))) (. .))
